Prospective study comparing XXXX or bevacizumab as adjuvant in trabeculectomy revision by needling.

@entity1 @entity4530 @entity1138 @entity726 @entity1493 @entity1139
PURPOSE: To compare the use of @entity1138 ( @entity1139 ) or bevacizumab ( @entity1493 ) as adjunctive in the needling revision of failed trabeculectomy blebs. METHODS: @entity726 @entity1 with failed trabeculectomy were included. @entity4530 were excluded. All procedures were performed by the same surgeon at the operating room under peribulbar blockade. Rate of success, intraocular pressure (IOP), and number of antiglaucoma drugs in use were compared before and after the procedures. The IOP was measured postoperatively at days 1, 30, 90, and 180. Absolute success was defined as IOP  <=18 mm Hg, without any complication or use of any antiglaucomatous drugs. Qualified success was the same criteria, but with the use of any antiglaucomatous drugs. RESULTS: Twenty-nine eyes of 29 @entity1 were included: 15 eyes with @entity1139 and 14 eyes with @entity1493 . There was no statistical difference in the IOP reduction between the groups ( @entity1139 32.6    16.1% vs @entity1493 30.1    12.0%, p = 0.6).  The @entity1493 group showed similar reduction in the number of antiglaucoma drugs compared to the @entity1139 group (p = 0.6). Absolute success was found in 28.5% of the @entity1493 group and in 6.6% of @entity1 with @entity1139 . Qualified success was found in 64.3% and 73.4%, respectively, both limited to 180 days. CONCLUSIONS: In this selected and limited group of @entity1 , bevacizumab can be considered as an alternative to @entity1139 in the needling revision of failed trabeculectomy. Studies with a larger number of @entity1 and longer follow-up are needed to confirm the hypothesis suggested here.
